Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-infection~* Antiretroviral therapy naïve, or if experienced, no treatment within 90 days of study screening and plan to remain off therapy for the duration of the screening and study treatment period~* HIV-1 RNA ≥ 5,000 copies/mL within 30 days of study Day 1~* CD4+ count ≥ 200 cells/mm³ within 30 days of study Day 1~* Agree to the use of two forms of adequate contraception for women, one form for men~* Estimated creatinine clearance \> 80 mL/min~* Serum creatinine \< 1.5 g/dL~* Able to give written informed consent prior to study start and adhere to study requirements~Exclusion Criteria:~* Active alcohol or drug use which in the opinion of the Investigator will likely compromise adherence to the study requirements~* A positive urine test for amphetamines, cocaine, and/or opioids~* Currently has any active AIDS defining illness (Category C condition according to the CDC Classification System for HIV Infection 1993)~* Any active clinically significant disease or findings during screening of medical history or physical examination that in the Investigator's opinion would compromise the outcome of the study~* Receiving oral concomitant antiviral or prophylactic drugs for opportunistic infections within 30 days prior to study entry~* Receiving concomitant treatment with nephrotoxic drugs (e.g., aminoglycosides \[tobramycin, gentamicin, and amikacin\], amphotericin B, vancomycin, cidofovir, foscarnet, cis-platinum, pentamidine), or competitors of renal excretion (e.g., probenecid) within 30 days of study entry~* Visual abnormalities (e.g. cataracts, macular degeneration) other than non-organic decreased visual acuity~* Receiving concomitant treatment with immunosuppressive drugs within 30 days prior to study entry~* Diabetes mellitus Type 1 or 2 which is being treated or not with any anti-diabetes agents~* Current significant gastrointestinal, renal, hepatic, bronchopulmonary, biliary, neurological, cardiovascular, oncologic, allergic, or ophthalmologic diseases including history of cataracts/lens opacities~* The following laboratory values performed within 30 days prior to study Day 1:~  * Hemoglobin \< 9.0 g/dL for men; 8.0 g/dL for women~ * Platelet count \< 75,000 cells per mL~ * Absolute neutrophil count \< 1,000 cells per mL~ * AST, ALT, alkaline phosphatase, and amylase \> 3 x ULN~ * Random or fasting glucose \> 121 mg/dL~ * Serum lipase \> 1.5 x ULN~ * Urinalysis ≥ 2+ proteinuria and ≥ 2 cellular casts per high powered field (HPF)~* Active acute hepatitis A and/or chronic hepatitis B or C with detectable viremia~* Subjects with clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels (INR \> 1.3 or albumin \< 30 g/l or bilirubin \> 2.5 x ULN)~* Pregnant women~* Breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).